UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 23476003.
- Also identified by DOI 10.1136/archdischild-2012-302153 and PMC identifier 3664378.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To assess persistence of immunity to hepatitis B (HBV) in primary school children vaccinated following perinatal exposure. Serological survey. Five UK sites (Berkshire East, Birmingham, Buckinghamshire, Milton Keynes and Oxfordshire). Children from 3 years 4 months to 10 years of age (mean age 6.2 years), vaccinated against HBV from birth following perinatal exposure. A single booster dose of the paediatric formulation of a recombinant HBV vaccine. Titres of antibody against hepatitis B Surface Antigen (anti-HBs) measured immediately before and 21-35 days after the HBV vaccine booster. Prebooster anti-HBs titres were >10 mIU/ml in 84.6% of children (n=26; 95% CI 65.1 to 95.6%). All children (n=25, 95% CI 86.3 to 100%) had titres >100 mIU/ml after the booster. This study of antibody persistence among UK children born to hepatitis B infected women, immunised with a 3-dose infant schedule with a toddler booster suggests sustained immunity through early childhood. These data should prompt further studies to address the need for a preschool booster. Eudract Number 2008-004785-98.
Medical subject headings
- Hepatitis B
- Hepatitis B Antibodies
- Hepatitis B Vaccines
- Immunization Schedule